Significant Revenue Increase
The company recorded a revenue of $550,000 for the first quarter of 2025, marking a 460% increase over Q1 2024.
Commercial Milestones Achieved
Perimeter achieved multiple commercial milestones including the first capital unit sale, record patient cases, and the highest number of consumables shipped.
Successful Pivotal Trial for B-Series
The pivotal trial for the B-Series OCT system met its primary endpoint with a statistically significant reduction in patients with residual cancer, achieving a margin accuracy of 88.1%.
FDA Pre-Market Approval Application
The company filed a pre-market approval application for the B-Series OCT with the FDA in March 2025 and engaged in positive dialogue with the agency.
Presentation at ASBrS Conference
Dr. Alastair Thompson presented detailed study results of the B-Series pivotal trial at the ASBrS conference, drawing significant attention from researchers and clinicians.